title: Anti-tumor necrosis factor α treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis.
authors.forename: Georgia
authors.initials: G
authors.lastname: Avgerinou
authors.forename: Dimitris
authors.initials: D
authors.lastname: Tousoulis
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Siasos
authors.forename: Evaggelos
authors.initials: E
authors.lastname: Oikonomou
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Maniatis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papageorgiou
authors.forename: Theodoros
authors.initials: T
authors.lastname: Paraskevopoulos
authors.forename: Antigoni
authors.initials: A
authors.lastname: Miliou
authors.forename: Dimitra
authors.initials: D
authors.lastname: Koumaki
authors.forename: George
authors.initials: G
authors.lastname: Latsios
authors.forename: Anastasia
authors.initials: A
authors.lastname: Therianiou
authors.forename: Athanasios
authors.initials: A
authors.lastname: Trikas
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Kampoli
authors.forename: Christodoulos
authors.initials: C
authors.lastname: Stefanadis
mesh_terms: D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab